LabCorp launches KRAS mutation analysis for new lung cancer therapy
LabCorp launches diagnostic for new lung cancer therapy | WRAL TechWire
Editor's note: LimeLight is a new feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link. BURLINGTON - Labcorp (NYSE: LH)'s new test expands the firm's testing solutions for new precision medicines used to treat patients with lung cancer.